These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28001228)

  • 21. Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate.
    Schubach Ade O; Marzochi KB; Moreira JS; Schubach TM; Araújo ML; Vale AC; Passos SR; Marzochi MC
    Rev Soc Bras Med Trop; 2005; 38(3):213-7. PubMed ID: 15895170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration.
    Alkhawajah AM; Larbi E; al-Gindan Y; Abahussein A; Jain S
    Ann Trop Med Parasitol; 1997 Dec; 91(8):899-905. PubMed ID: 9579209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of lesion improvement in lupoid leishmaniasis patients with two treatment approaches: trichloroacetic Acid and intralesional meglumine antimoniate.
    Banihashemi M; Yazdanpanah MJ; Amirsolymani H; Yousefzadeh H
    J Cutan Med Surg; 2015; 19(1):35-9. PubMed ID: 25775661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.
    Rubiano LC; Miranda MC; Muvdi Arenas S; Montero LM; Rodríguez-Barraquer I; Garcerant D; Prager M; Osorio L; Rojas MX; Pérez M; Nicholls RS; Gore Saravia N
    J Infect Dis; 2012 Feb; 205(4):684-92. PubMed ID: 22238470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial.
    Ramalho DB; Silva RED; Senna MCR; Moreira HSA; Pedras MJ; Avelar DM; Saraiva L; Rabello A; Cota G
    Mem Inst Oswaldo Cruz; 2018 Jun; 113(9):e180200. PubMed ID: 29947651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
    Shazad B; Abbaszadeh B; Khamesipour A
    Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment.
    Silva RED; Carvalho JP; Ramalho DB; Senna MCR; Moreira HSA; Rabello A; Cota E; Cota G
    Mem Inst Oswaldo Cruz; 2018 Feb; 113(2):71-79. PubMed ID: 29236929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intralesional injections of meglumine antimoniate to treat complex facial leishmania infantum acquired in Spain: a case report.
    Mostmans Y; Van Gysel J; Vanden Nest H; Mervillie K; Richert B; Clevenbergh P
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e548-e550. PubMed ID: 35181939
    [No Abstract]   [Full Text] [Related]  

  • 29. Plasma antimony determination during cutaneous leishmaniasis treatment with intralesional infiltration of meglumine antimoniate.
    de Aguiar MG; Gonçalves JE; Souza MD; de Silva RE; Silveira JN; Cota G
    Trop Med Int Health; 2018 Oct; 23(10):1110-1117. PubMed ID: 30053341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of Localized Cutaneous Leishmaniasis With Intralesional Meglumine Antimoniate and Photodynamic Therapy.
    Costin A; Bonito F; Alves J; Barreiros H
    Actas Dermosifiliogr (Engl Ed); 2020 Dec; 111(10):897-899. PubMed ID: 32473104
    [No Abstract]   [Full Text] [Related]  

  • 31. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
    Demicheli C; Ochoa R; da Silva JB; Falcão CA; Rossi-Bergmann B; de Melo AL; Sinisterra RD; Frézard F
    Antimicrob Agents Chemother; 2004 Jan; 48(1):100-3. PubMed ID: 14693525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of acute cutaneous leishmaniasis with intralesional injection of meglumine antimoniate: comparison of conventional technique with mesotherapy gun.
    Kashani MN; Sadr B; Nilforoushzadeh MA; Arasteh M; Babakoohi S; Firooz A
    Int J Dermatol; 2010 Sep; 49(9):1034-7. PubMed ID: 20883265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.
    Ribeiro MN; Pimentel MI; Schubach Ade O; Oliveira Rde V; Teixeira JL; Leite MP; Fonseca M; Santos GP; Salgueiro MM; Ferreira e Vasconcellos Ede C; Lyra MR; Saheki MN; Valete-Rosalino CM
    Rev Inst Med Trop Sao Paulo; 2014; 56(4):291-6. PubMed ID: 25076428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline.
    Báfica A; Oliveira F; Freitas LA; Nascimento EG; Barral A
    Int J Dermatol; 2003 Mar; 42(3):203-7. PubMed ID: 12653916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Side effects of meglumine antimoniate in cutaneous leishmaniasis: 15 cases].
    Ezzine Sebai N; Mrabet N; Khaled A; Zeglaoui F; Kharfi M; Fazaa B; Kamoun MR
    Tunis Med; 2010 Jan; 88(1):9-11. PubMed ID: 20415206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follicular mucinosis associated with cutaneous leishmaniasis.
    Abajo P; Martín R; Daudén E
    Acta Derm Venereol; 1998 Jul; 78(4):315. PubMed ID: 9689315
    [No Abstract]   [Full Text] [Related]  

  • 37. Effectiveness of intralesional meglumine antimoniate in the treatment of mucosal leishmaniasis of the Old World.
    Zaraa I; Karoui S; Osman AB
    J Dermatol; 2012 Feb; 39(2):201-3. PubMed ID: 21950659
    [No Abstract]   [Full Text] [Related]  

  • 38. An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil.
    Oliveira-Ribeiro C; Pimentel MIF; Oliveira LFA; Vasconcellos ÉCFE; Conceição-Silva F; Schubach AO; Fagundes A; de Mello CX; Mouta-Confort E; Miranda LFC; Valete-Rosalino CM; Martins ACDC; Oliveira RVC; Quintella LP; Lyra MR
    PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009734. PubMed ID: 34555016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R; Handjani F; Nouhpisheh MK
    J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults.
    Layegh P; Rahsepar S; Rahsepar AA
    Am J Trop Med Hyg; 2011 Apr; 84(4):539-42. PubMed ID: 21460006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.